Detalhe da pesquisa
1.
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Invest New Drugs
; 33(6): 1187-96, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26403509
2.
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Nat Med
; 13(9): 1102-7, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17767166
3.
Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Drug Metab Dispos
; 41(4): 714-26, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23305709
4.
The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
Clin Pharmacol Ther
; 75(5): 464-75, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116059